VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

Nature Medicine

Volumn 7, Issue 2, 2001, Pages 186-191

  Stacker, Steven A ^a   Caesar, Carol ^a   Baldwin, Megan E ^a   Thornton, Gillian E ^a   Williams, Richard A ^b   Prevo, Remko ^c   Jackson, David G ^c   Nishikawa, Shin Ichi ^d   Kubo, Hajime ^d,e   Achen, Marc G ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENDOTHELIUM CELL; FEMALE; GROWTH REGULATION; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; CELL LINE, TRANSFORMED; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

ANIMALIA;

EID: 0035126049     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/84635     Document Type: Article

References (41)

1. Cancer cell invasion and metastasis
2. Angiostatin: A novel angiogenesis inhibitor that mediates the supression of metastases by a lewis lung carcinoma
3. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
4. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant
5. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
6. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
7. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
8. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4)
9. Identification of a C-Fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family
10. Expression of the Fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
11. Vascular endothelial growth factor receptor-3
12. The classification of cancer of the rectum
13. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
14. The vascular endothelial growth factor family: Signaling for vascular development
15. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers
16. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3
17. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
18. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
19. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination
20. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
21. The role of natural killer cells in immune surveillance of cancer
22. Antitumor functions of natural killer cells and control of metastases
23. Host NK cells are required for the growth of the human filarial parasite Brugia malayi in mice
24. Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a Patent Blue V injection: A multicenter study
25. Anti-angiogenesis: New concepts of therapy of solid tumors
26. Angiogenic factors
27. What is the evidence that tumors are angiogenesis dependent?
28. Blood vessel formation: What is its molecular basis?
29. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
30. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
31. Growth factors regulating lymphatic vessels
32. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation
33. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
34. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
35. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
36. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
37. Localisation of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
38. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
39. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma
40. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis
41. Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both the immunoglobulin-like domain and the cytokine receptor homologous domain